Cancer Immunotherapy News and Research

RSS

New approach to immunotherapy provokes a robust anti-tumor immune response in preclinical models

A new approach to cancer immunotherapy that uses one type of immune cell to kill another-;rather than directly attacking the cancer-;provokes a robust anti-tumor immune response that shrinks ovarian, lung, and pancreatic tumors in preclinical disease models, according to researchers at the Icahn School of Medicine at Mount Sinai in New York.

25 Oct 2022

Study determines how fibroblasts play a role in tumor's ability to generate anti-HER2 therapy resistance

A study led by researchers at the Hospital del Mar Medical Research Institute (IMIM-Hospital del Mar) has determined the role that fibroblasts, the cells that contribute to tissue formation, play in a tumor's ability to generate resistance to the most common biological treatment for HER2.

14 Oct 2022

UNO-peptide-modified CCN shows promise for targeted delivery of TAM immunomodulatory agents

Announcing a new publication for Acta Materia Medica journal. Tumor-associated macrophages (TAMs) are key contributors to tumor development, accelerated tumor invasion and metastasis, and induction of immunosuppression.

13 Oct 2022

Diet plays an important role in the success of immunotherapy

Eating a Mediterranean diet, rich in fiber, mono-unsaturated fatty acids and polyphenols, has been associated with improved immunotherapy response rates and progression-free survival in advanced melanoma patients, a new study presented today at UEG Week 2022 has found.

10 Oct 2022

Transient cell-in-cell formation by tumor cells found to build resistance to immunotherapy

Researchers demonstrated that tumor cells evade immunotherapy by generating unique transient cell-in-cell structures, resistant to chemotherapy and destruction by T cells.

5 Oct 2022

Shape-shifting mitochondria influence Th17 cells’ propensity for autoimmune activity

A new study focused on the immune system's Th17 cells suggests that the shape and function of their mitochondria (the powerhouse of cells) is important in autoimmune and inflammatory disorders, such as multiple sclerosis.

28 Sep 2022

Public-private collaboration receives grant for research on microbiota-boosted cancer therapy

Health~Holland has awarded close to € 800,000 to a public-private partnership between UMC Utrecht, Artizan Biosciences, Inc. (USA) and MicroViable Therapeutics (Spain) to unravel how the intestinal microbiota can be exploited to boost cancer immunotherapy and limit therapy side-effects.

21 Sep 2022

Tumors generate unique, temporary cell-in-cell structures to evade immunotherapy

Scientists have shown how tumour cells evade immunotherapy by generating unique, temporary cell-in-cell structures, where the inner cells remain in tact and can return to single tumour cells.

20 Sep 2022

Research could lead to a new therapeutic option for patients with bladder cancer

Mount Sinai researchers have made two important discoveries about the mechanism by which bladder cancer cells foil attacks from the immune system.

12 Sep 2022

Pollutant particles in the air trigger lung cancer in non-smokers

A new mechanism has been identified through which very small pollutant particles in the air may trigger lung cancer in people who have never smoked, paving the way to new prevention approaches and development of therapies, according to late-breaking data [to be] reported at the ESMO Congress 2022 by scientists of the Francis Crick Institute and University College London, funded by Cancer Research UK. The particles, which are typically found in vehicle exhaust and smoke from fossil fuels, are associated with non-small cell lung cancer (NSCLC) risk, accounting for over 250,000 lung cancer deaths globally per year.

12 Sep 2022

Administering immunotherapy drug before surgery for oral cavity cancer did not increase complications

A University of Cincinnati study found administering an immunotherapy drug before surgery for oral cavity cancer did not lead to increased rates of complications during and after surgery.

7 Sep 2022

Lactate may have a previously unrecognized role in fighting cancer

A new study by UT Southwestern's Simmons Cancer Center scientists suggests that lactate, a metabolic byproduct produced by cells during strenuous exercise, can rejuvenate immune cells that fight cancer.

6 Sep 2022

Study reveals a novel therapeutic strategy to overcome tumor-induced immunosuppression

A study led by LSU Health New Orleans cancer researchers describes a novel therapeutic strategy to overcome tumor-induced immunosuppression.

29 Aug 2022

New approach using CRISPR can engineer massive quantities of cells for therapeutic applications

A new variation of the CRISPR-Cas9 gene editing system makes it easier to re-engineer massive quantities of cells for therapeutic applications.

25 Aug 2022

Using the power of CRISPR to engineer better, stronger, longer-lived T cells

T cells used in immunotherapy treatments can get exhausted by the task of fighting cancer cells or get shutdown as they enter tumors.

24 Aug 2022

Ian Frazer Centre for Children’s Immunotherapy Research aims to advance pediatric cancer care

Australia's first dedicated children's immunotherapy center will investigate treatments to not only increase the survival of kids with cancer, but to also improve their ongoing quality of life.

24 Aug 2022

Discovery points to new drug targets that could prevent cancer spread

Any cancer cell migrating from a tumor to set up shop elsewhere in the body will face a brutal attack from an immune system programmed to seek and destroy abnormal cells.

22 Aug 2022

Study paves new way to develop a predictive biomarker for TRAIL therapy

A cytokine named TRAIL binds to TRAIL receptors and kills cancer cells, but not normal cells. Therefore, various anticancer drugs targeting TRAIL receptors have been developed and gained great attention as a promising cancer therapeutics, but a certain population of cancer patients does not respond to the therapy.

15 Aug 2022

PET imaging could help measure the pharmacodynamic effects of using STING-activating drugs

Stimulator of interferon genes, or STING, helps regulate immune activation. Thus, drugs that activate STING are being tested as a form of cancer immunotherapy and for treating certain infections.

11 Aug 2022

Research may lead the way to a simpler treatment for cancer

Sometimes too much of a good thing is not good at all. Inhibiting the function of the PD-1 protein, which blocks immune function, has shown high therapeutic efficacy in cancer immunotherapy.

10 Aug 2022